Metabolic profiling indicates stage-specific reprogramming, differentiated thyroid cancers (e.g., PTC-B and FTC-R) show mutation-associated metabolic signatures (BRAF, RAS), whereas ATC favors one-carbon and pyrimidine metabolism, reflecting shifts that support rapid growth and aggressiveness [59]. This evidence concerns the gene BRAF and thyroid cancer.